Bioprinted tumors for commercial drug testing
CompanyCarcinotech Ltd., Edinburgh, United Kingdom
Carcinotech offers assay-ready 3D-printed tumors for drug discovery, screening and preclinical testing. The innovative Carcino3D™ technology is validated and enables high throughput due to robotic manufacturing. Since the tumors are produced from patient biopsies, they reflect the heterogeneity of the original tumor. Tumors printed with Carcino3D™ are self-forming and ready for testing within 7-14 days of printing. They can be made to order, cryopreserved and shipped to other laboratories ready for testing. A team of 3D oncology experts also provides assay services for each agent using Carcino3D™ technology. In addition, tumors can be adapted to drug tests, e.g. for specific patient groups, mutation types, drug targets or treatments.
Personalised medicine & assay services
info@carcinotech.co.uk
Added on: 01-30-2023
[1] https://www.carcinotech.co.uk/personalised-medicine-assay-services/[2] https://www.cellink.com/customer-spotlight/bioprinting-patient-specific-tumor-models-for-individualized-drug-testing/
